Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Santen Pharmaceutical Co ( (JP:4536) ) has provided an announcement.
Santen Pharmaceutical reported a slight decline in revenue for the year ended March 31, 2026, but achieved growth in operating profit, net profit, and earnings per share, alongside improved profitability ratios and a stronger equity base. Cash flows from operating activities fell, yet the company maintained a solid financial position and continued to return cash to shareholders through stable dividends, with annual payouts rising and payout ratios remaining in the low-30% range.
Looking ahead to the fiscal year ending March 31, 2027, Santen forecasts a return to top-line growth with revenue expected to increase 6.6% and core operating profit up 7.0%, supporting a further rise in earnings per share and an enhanced dividend. The projections suggest confidence in operational momentum and reinforce Santen’s commitment to shareholder returns, indicating a strategy of balancing investment in growth with steady income for investors.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2600.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., listed on the Tokyo Stock Exchange Prime Market, operates in the pharmaceutical industry with a focus on eye care. The company develops and markets ophthalmic treatments and related healthcare products, positioning itself as a specialized player in the global ophthalmology market.
Average Trading Volume: 938,242
Technical Sentiment Signal: Buy
Current Market Cap: Yen520.6B
See more insights into 4536 stock on TipRanks’ Stock Analysis page.